Key Points
- Thermo Fisher VP Lisa Britt sold 11,440 shares at an average price of $613.12, generating approximately $7.01 million. The sale reduced her direct ownership by 43.62% to 14,784 shares.
- The company reported strong quarterly results, with revenue rising 10.5% year over year to $11.99 billion and EPS of $6.03, beating analysts’ estimate of $5.71. Shares opened at $629.02, near the company’s 52-week high of $643.99.
- Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $619.41. Thermo Fisher also declared a quarterly dividend of $0.47 per share, equivalent to a 0.3% annualized yield.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) VP Lisa Britt sold 11,440 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Thermo Fisher Scientific Stock Up 0.2%
Shares of TMO opened at $629.02 on Friday. The stock's 50-day moving average price is $542.53 and its 200-day moving average price is $509.70. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $232.58 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the business earned $4.28 earnings per share. The firm's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.
Institutional Trading of Thermo Fisher Scientific
Several hedge funds have recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID raised its holdings in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Kilter Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $26,000. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 89.23% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and cut their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Royal Bank Of Canada raised their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $619.41.
View Our Latest Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
